Genetic profile of ductal adenocarcinoma of the prostate.
暂无分享,去创建一个
B. Delahunt | H. Samaratunga | J. Lindberg | H. Grönberg | L. Egevad | Thomas Whitington | P. Wiklund | A. Seipel | M. Mayrhofer | Amanda H. Seipel
[1] M. Rubin,et al. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. , 2016, European urology.
[2] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[3] J. Hicks,et al. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas , 2015, The Prostate.
[4] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[5] J. Squire,et al. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. , 2014, Cancer genetics.
[6] Chris Sander,et al. Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.
[7] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[8] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[9] I. Thompson,et al. Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer , 2013, The Prostate.
[10] R. Eeles,et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[12] L. Egevad,et al. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens , 2013, Virchows Archiv.
[13] T. H. van der Kwast,et al. Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression* , 2013, Molecular & Cellular Proteomics.
[14] J. Lindberg,et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. , 2013, European urology.
[15] G. Kristiansen,et al. Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression. , 2012, Human pathology.
[16] Jennifer R. Rider,et al. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[17] Jianfeng Xu,et al. Suppression of Tak1 promotes prostate tumorigenesis. , 2012, Cancer research.
[18] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[19] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[20] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[21] J. Cashy,et al. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program , 2012, BJU international.
[22] Wei Li,et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. , 2011, Cancer research.
[23] M. Shen,et al. Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.
[24] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[25] P. Humphrey,et al. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate , 2009, Modern Pathology.
[26] E. Platz,et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas , 2009, Modern Pathology.
[27] P. Ekman,et al. Expression of PDX‐1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[28] Rocío Martín,et al. Effect of Prolactin and Bromocriptine on the Population of Prostate Neuroendocrine Cells from Intact and Cyproterone Acetate‐Treated Rats: Stereological and Immunohistochemical Study , 2007, Anatomical record.
[29] Jin Woo Kim,et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.
[30] Mahul B Amin,et al. Update on the Gleason Grading System for Prostate Cancer: Results of an International Consensus Conference of Urologic Pathologists , 2006, Advances in anatomic pathology.
[31] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[32] C. Ormandy,et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. , 2003, Endocrinology.
[33] J. Epstein,et al. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. , 1999, The American journal of surgical pathology.
[34] D. Bostwick,et al. Does prostatic ductal adenocarcinoma exist? , 1999, The American journal of surgical pathology.
[35] C. Hänni,et al. Molecular phylogeny of the ETS gene family , 1999, Oncogene.
[36] P. Walsh,et al. Prostatic duct adenocarcinoma. Findings at radical prostatectomy , 1991, Cancer.
[37] G. Farrow,et al. Prostatic adenocarcinoma of ductal origin , 1973, Cancer.
[38] Jonathan I. Epstein,et al. WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .
[39] S. Brewster,et al. Wnt signalling and prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.